前列腺特异性抗原的放免测定在前列腺疾病中的应用

Radioimmunoassay of Prostate Specific Antigen in Patients with Prostate Disease

采用放射免疫分析法测定了６７例前列腺疾病患者及３０例其它肿瘤（直肠癌、膀胱癌等）及女性生殖系统肿瘤患者与５４例正常人血中的前列腺特异性抗原（ＰＳＡ）的浓度，以探讨其在前列腺疾病中的应用价值。结果显示：前列腺增生（ＢＰＨ）、前列腺硬结可疑癌及前列腺癌（ＰＣ）患者血清ＰＳＡ水平均显著高于正常对照组（Ｐ＜０．０１）且ＰＣ患者血清ＰＳＡ水平大部分大于４０μｇ／Ｌ，显著高于ＢＰＨ和前列腺硬结可疑癌患者（Ｐ＜０．０１），而其它肿瘤及女性生殖系统肿瘤患者血清ＰＳＡ水平则无明显升高（Ｐ＞０．０５）。因而认为血清ＰＳＡ的放免测定可为前列腺疾病的临床诊断提供可靠依据。

To evaluate the value of prostate specific antigen(PSA)for detecting prostatic disease (PD),the serum PSA concentrations were measured by radioimmunoassay(RIA) in 67 PD patients, 30 patients with other cancer(e.g. rectal cancer,bladder cancer,female genital system tumor,etc.)and 54 normal controls.Results showed as follows: 1) the contents of serum PSA in PD patients were significantly higher than those in other cancer patients and normal controls( P <0.01);2)the contents of serum PSA in patients with prostate cancer were greatly increased than those in patients with benign prostatic hyperplasia(BPH) and suspicious prostate cancer among PD patients( P <0.001); 3) the contents of serum PSA in patients with other cancer were not significantly elevated as compared with those of the control group( P >0.05).It is concluded that the PSA RIA is a reliable approach for the clinical diagnosis of PD.